Overview

Co-administration of Low Dose hCG at the Time of GnRH Agonist Trigger or 35 Hours Later for the Prevention of OHSS

Status:
Completed
Trial end date:
2016-10-01
Target enrollment:
Participant gender:
Summary
This a prospective randomized double blind study involving patients at high risk of OHSS development with peak serum E2 levels < 4,000 pg/ml comparing the ongoing pregnancy rates in patients who receive adjuvant hCG 1,000 IU at the time of GnRH agonist trigger or adjuvant hCG 1,500 IU 35 hours after GnRH agonist trigger.
Phase:
Phase 4
Details
Lead Sponsor:
UConn Health
Collaborator:
Merck Sharp & Dohme Corp.
Treatments:
Chorionic Gonadotropin
Deslorelin
Triptorelin Pamoate